Genesis · fair launch

$DeCure: a trillion-dollar science fund on Solana.^*

DeCure searches approved medicines for new uses. AI maps the biology. Our AI folds the strongest candidates. Real labs test what survives. The evidence goes public.

5,000 diseases. One billion tokens. One open research machine.

$DECURE 5,000 disease maps 12 research labs Open evidence

Explore 5,000 diseases See the Labs Read the protocol

*“Trillion-dollar” describes the mission — channelling research money into drug repurposing published open-access. It is not a price target, forecast or promise about the token. No presale, no team allocation. $DECURE carries no equity, dividend, royalty or claim on revenue or research, and can lose all value.

What is DeCure

The next useful drug may already exist.

Most drug discovery begins by inventing a new molecule. DeCure asks a different question: what can medicines already known to science do that nobody has seriously tested yet?

How it works

Find it. Fold it. Test it. Publish it.

1

Map

Build a disease model from genes, pathways, targets, trials and primary literature.

2

Find

Rank approved drugs and combinations against the biology of the disease.

3

Fold

Use our AI on the protocol’s own compute to model the strongest drug–target pairs.

4

Test

Send the best surviving hypotheses into binding, biochemical and cellular assays.

5

Publish

Release the methods, raw evidence and paper so anyone can inspect the result.

Protocol token

$DECURE: your vote on the research.

Choose the lab. Choose the disease. $DECURE is the vote that decides where the research goes. Stake it and you share up to half of every trading fee, paid in SOL.

Solana protocol

Stake for a disease, not a logo.

Genesis supply

1 billion $DECURE. Fixed from day one.

1 billion total supply, minted once and launched on the open market. No presale, no team allocation, no reserve.

1B

Fixed supply

Minted once. Never again.

0%

Team, presale or reserve

Every token enters the market the same way.

Lab 01

Cancer Lab

Lab 01 — Cancer

Find combinations that change tumour biology.

Search approved drugs and combinations for biomarker-defined tumours, resistance mechanisms and treatment windows — then take the strongest candidate into a real assay and publish the evidence.

Drug repurposing Biomarkers Combination protocols Open evidence

First 12 labs

The first twelve labs.

Each lab owns a disease area, a research queue and one question: which approved medicines deserve a real experiment here?

Lab #	Lab	Lab mandate	First research wedge	Why it matters
1	$DeCureCancer Lab	Invent oncology treatment combinations from approved drugs.	Approved-drug cocktails, biomarker gates, dosing windows and combination protocols.	Drug repurposing lowers discovery cost and targets known safety profiles.
2	$DeCureLongevity Lab	Repurpose approved drugs for healthy ageing and longevity.	Approved geroprotectors and combinations with ageing biomarkers.	Strong repurposing precedent and approved-drug safety; measurable ageing biomarkers.
3	$DeCureRare Lab	Repurpose approved drugs for rare and orphan diseases.	Approved drugs matched to rare-disease mechanisms via white-space mapping.	High unmet need, regulatory incentives and approved-drug safety.
4	$DeCureAMR Lab	Fight antimicrobial resistance.	Approved antibiotic + adjuvant combinations, resistance reversal protocols.	Focus on combinations and dosing logic rather than de novo molecules.
5	$DeCureNeuro Lab	Target Alzheimer's, Parkinson's and neuroinflammation.	Repurposed compounds against neuroinflammation, protein homeostasis and synaptic function.	Uses multi-modal data and known mechanisms to create new-use findings.
6	$DeCureMetabolic Lab	Address obesity, diabetes and metabolic aging.	Approved metabolic drugs and combinations for diabetes, obesity and MASH.	High data availability and measurable endpoints.
7	$DeCureNephro Lab	Repurpose approved drugs for kidney and fluid disorders.	Approved drugs matched to CKD and fluid-disorder mechanisms.	Large populations, measurable endpoints and approved-drug safety.
8	$DeCureImmuno Lab	Target autoimmune and inflammatory disease.	Approved immunomodulators and combinations with biomarker stratification.	Known mechanisms and approved-drug safety enable new-use findings.
9	$DeCureDerma Lab	Repurpose approved drugs for skin disease.	Approved drugs, topical reformulations and combinations.	Approved-drug safety and measurable skin endpoints lower cost.
10	$DeCureResp Lab	Target COPD, asthma and pulmonary fibrosis.	Approved drugs and combinations matched to respiratory mechanisms.	Approved-drug safety and measurable respiratory endpoints.
11	$DeCurePsych Lab	Repurpose approved compounds for psychiatric and CNS disorders.	Repurposed compounds and combinations with patient stratification.	Known mechanisms and approved-drug safety enable new-use findings.
12	$DeCureCardio Lab	Target heart failure, atherosclerosis and cardiometabolic disease.	Approved drugs and combinations matched to cardiovascular mechanisms.	Large populations, hard endpoints and approved-drug safety.

The first 12 labs

12 labs.
5,000 diseases.
One shared engine.

All twelve run on the same evidence, folding and publication infrastructure. Staking directs attention across them; evidence decides what moves forward.

L01

$DeCureCancerCancer combinations

L02

$DeCureLongevityLongevity & ageing

L03

$DeCureRareRare & orphan

L04

$DeCureAMRResistance reversal

L05

$DeCureNeuroNeurodegeneration

L06

$DeCureMetabolicDiabetes & MASH

L07

$DeCureNephroKidney & fluids

L08

$DeCureImmunoAutoimmune & inflammation

L09

$DeCureDermaDermatology

L10

$DeCureRespRespiratory

L11

$DeCurePsychPsychiatry & CNS

L12

$DeCureCardioCardiovascular

Trading fees

Every trade pays the research — and the stakers.

Up to half of every trading fee goes to stakers, paid in SOL. The other half funds the research — $150K for every DeCure the community picks: $50K in silico, $50K for the PhD and the paper, $50K in vitro. All of it published in the open.

How each DeCure protocol release is divided across folding, staking and research

How the science works

The AI can't grade its own homework.

1

Generate

Proposes approved-drug candidates, grounded in the literature and drug–target data.

2

Score

A separate engine scores each one on structured biology: signature reversal, network proximity, known pharmacology. The language model does not grade its own output.

3

Run

Writes and runs real analysis code in a sandbox, on real public datasets.

4

Prove

Benchmarked against known repurposings held out from the model — measured, not claimed.

5

File

Only verified candidates become open-access papers.

Open evidence

No black box. No victory lap without data.

Methods, raw data and analysis are released as an open research package. Positive and negative results both count when the experiment was sound.

Open-accessResults are published so anyone can inspect, reproduce or continue the work.

Negative results tooA well-executed negative result closes a path and improves the next decision.

No ownership claim$DECURE carries no equity, dividend, royalty or claim on a paper, patent or laboratory.

The lab decidesA computational result earns attention. Only experimental evidence earns confidence.

Map it → Fold it → Test it → Publish it → repeat.

Open research record: published papers, raw data and results

Roadmap

Start simple. Prove each layer.

Phase 1 Token

A fixed-supply Solana token launched on the open market, with official addresses published on-chain.

Phase 2 Fold & stake

Staking lets holders direct research across the twelve labs, and $DECURE funds the folding.

Phase 3 Wet lab

The research budget funds the first real experiment, and the evidence goes into the open research record.

Each module ships with its own public status and official address. Nothing here is financial, legal or investment advice.

One token

Compute. Direction. Research.

There is one public token, and it is a vote. Stake $DECURE to choose which of the twelve labs gets more compute; commit it to a DeCure to choose which disease goes to the lab first. Every trade funds the folding, the wet lab and the publication. It carries no equity, dividend, royalty or claim on a paper, patent or laboratory.

FAQ

Questions people ask first.

Has DeCure cured a disease?Not yet. The first target is a complete wet-lab result with public data. Every candidate stays a research hypothesis until an experiment says otherwise.

Do holders own the papers?No. Results are published open-access and owned by no one. $DECURE coordinates the work — it is not equity, a royalty or title to a paper.

Is $DECURE an investment?It is a research protocol token, not a share or a security: you vote with it on which lab and which disease DeCure researches, and stakers share up to half of every trading fee in SOL. It is volatile and can lose all its value. Do your own research.

Who is behind DeCure?AnonDev — an independent bioinformatician building the research stack in public. Judge the project by the code, the data and the experiments, not by a name.

What chain?Solana.

Disclaimer & risk notice

Nothing here is an offer, solicitation or recommendation to buy any asset, or financial, investment, legal, tax or medical advice. $DECURE and all DeCure tokens are experimental utility / community tokens on Solana — not shares, securities, equity, debt, fund units, or claims to revenue, royalties, dividends or profit, and they confer no ownership of any paper or of DeCure. DeCure outputs are AI-generated research hypotheses and peer-reviewed papers — not validated treatments, clinical advice, or proof of safety or efficacy; any drug or candidate named is unapproved for the stated use. Forward-looking statements and roadmap targets are aspirations, not promises, and may never occur. Crypto assets are highly volatile and can go to zero. You alone are responsible for your decisions and for complying with the laws of your jurisdiction; participation is void where prohibited. Always do your own research.

X.com Telegram Addresses

$DeCure: a trillion-dollar science fund on Solana.*